Chapter 4 Central nervous system

The clinical guidance contained in the linked documents is believed to be true and accurate at the point of preparation. New evidence/ guidance is continually released which may supersede this information; please use your own clinical and professional judgement when reading or acting on any information contained.

• Alcohol Detox Guidance approved 2025.pdf [pdf] 632KB
• Antidepressant Guidelines approved 2020.pdf [pdf] 199KB
• Antipsychotics - ECG monitoring for adults (approved July 2018).pdf [pdf] 33KB
• Antipsychotics - Depot or LAI by unlicensed route (Approved May 18).pdf [pdf] 20KB
• Antipsychotics - CAMHS Information and record book for Young People and their families.pdf[pdf] 627KB
• Antipsychotics - CAMHS Reference card. Evidence base regarding side effects in children and young people.pdf[pdf] 131KB
• Antipsychotic - High Dose Therapy Checklist (approved 2020).pdf [pdf] 252KB
• Antipsychotic - High Dose Therapy Monitoring Sheet (approved 2020).pdf [pdf] 412KB
• Antipsychotic - High Dose Therapy Prescribing Guidance (approved 2020).pdf [pdf] 745KB
• Antipsychotics & Mood Stabilsers - Summary monitoring guidance for adults (approved 2022).pdf [pdf] 600KB
• Antipsychotics and plasma level monitoring incl smoking effects November 2020.pdf [pdf] 248KB
• Antipsychotics - Prescribing Guidance (approved 2015).pdf [pdf] 567KB
• Antipsychotics - Unlicensed use in unipolar depression (approved 2010).pdf [pdf] 25KB
• Antipsychotics - Unlicensed use of atypicals in the treatment of Generalised Anxiety Disorder (approved 2011).pdf [pdf] 41KB
  • Antipsychotics - POMH Ready Reckoner (LATEST version) (The POMH Ready Reckoner is available to Coventry and Warwickshire Partnership NHS Trust staff only. This link will re-direct you to the Trust intranet)
  • Aripiprazole long acting injection (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
  • Atomoxetine – Shared Care Agreement SCA002
• Baclofen - Unlicensed use for the maintenance of abstinence from alcohol (approved 2011).pdf [pdf] 25KB
• Buccal Midazolam or Rectal Diazepam - Treatment of seizures (approved 2016).pdf [pdf] 189KB
• Bupropion - Unlicensed use in depression (approved 2009).pdf [pdf] 33KB
• Bupropion - Unlicensed use in adults with ADHD (approved 2011).pdf [pdf] 35KB
• Buspirone - Unlicensed use in treatment resistant depression (approved 2011).pdf [pdf] 59KB
• Cannabis based products for medicinal use - Prescribing position - Nov 2018.pdf [pdf] 85KB
• Citalopram and Escitalopram - Unlicensed prescribing when contraindicated due to QTc (approved 2012.pdf [pdf] 356KB
• Citalopram and Escitalopram - Unlicensed use where there is a contraindication due to QTc issues (approved 2012).pdf [pdf] 33KB
• Clonidine - Unlicensed use in childhood sleep disturbances (approved 2010).pdf [pdf] 28KB
• Clonidine - Unlicensed use in Hypersalivation caused by Clozapine (approved 20 11).pdf [pdf] 28KB
• Clozapine - Alternatives to Hyoscine for Clozpaine induced hypersalivation (approved 2017).pdf [pdf] 88KB
• Clozapine change intervention leaflet.pdf [pdf] 236KB
• Clozapine - Community initiation - Approved Sept D&T 2023 revised March 25.pdf [pdf] 812KB
• Clozapine - Inpatient Initiation Guidance Approved February 2024 revised Sept 24.pdf [pdf] 732KB
• Clozapine - Unlicenced use after a red blood result (approved 2011).pdf [pdf] 30KB
• Clozapine - Unlicensed use in the treatment of resistant psychotic depression (approved 2010).pdf [pdf] 34KB
• Dementia Medicines - Prescribing Algorithm Across the primary and secondary care interface (2020).pdf [pdf] 54KB
• Dexamfetamine – Shared Care Agreement SCA003 (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Domperidone checklist children 24th February 2020.pdf 379KB
• Esketamine DPS post July 2020 D&T Discussion .pdf [pdf] 260KB
• Epilepsy - Care Plan (approved 2015).pdf [pdf] 423KB
• Fluoxetine - Unlicensed use in the treatment of anxiety in autistic children (approved 2010).pdf [pdf] 41KB
  • Fluoxetine – Shared Care Agreement SCA048(This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Hyperprolactinaemia APD Algorithm approved D&T January 2019.pdf [pdf] 86KB
• Hyoscine - Unlicensed use in hypersalivation caused by Clozapine (approved 2009).pdf [pdf] 31KB
• Lamotrigine - Unlicensed use in the treatment of borderline personality disorder (approved 2011).pdf [pdf] 31KB
• Lithium - Prescribing Guidance (approved 2017).pdf [pdf] 283KB
  • Lithium – Shared Care Agreement SCA005 (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
  • Lurasidone – Drug Position Statement (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Melatonin for children - Prescribing Support Information Approved D&T March 23 updated March 2024.pdf [pdf] 394KB
  • Melatonin Specialist Initiation Drug Checklist (SIDC)  (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Methylphenidate – Shared Care Agreement SCA001  (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Methylphenidate - Brand change letter Concerta to Xaggitin.pdf [pdf] 240KB
• Methylphenidate MR formulation review - Jan 2025 D&T.pdf [pdf] 220KB
• Metformin - Unlicensed use to prevent antipsychotic-induced weight gain (approved Sept 2016).pdf [pdf] 174KB
• Naltrexone - Unlicensed use in alcohol dependence (approved 2011).pdf [pdf] 42KB
• Naltrexone - Unlicensed use in self injurious behaviour (approved 2009).pdf [pdf] 31KB
• Nicotine Replacement Therapy - General Prescribing and Usage Advice V1.3.pdf [pdf] 228KB
• Nicotine Replacement Therapy - Administration Record for PRN products (approved 2015).pdf [pdf] 180KB
• NRT or ENDS admin prior to prescription v1.2 approved Nov 2020.pdf [pdf] 337KB
• Guidance for the Recommended Supply of Nicotine Replacement Therapy (NRT) to Clients Aged 12 and Over.pdf [pdf] 791KB
• Olanzapine Depot (Zypadhera) - Drug position statement (approved 2014).pdf [pdf] 281KB
• Opiods - Patient Information Leaflet (2015).pdf [pdf] 227KB
• Oxcarbazepine - Unlicensed use in the treatment of bipolar affective disorder (approved 2010).pdf [pdf] 37KB
• Paliperidone ER Tablets (Invega) - Treatment of Schizophrenia.pdf [pdf] 186KB
• Paliperidone Palmitate Long Acting Injection – 1 and 3 monthly. (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Penfluridol - Evidence for use in the treatment of schizophrenia (approved 2015).pdf [pdf] 32KB
• Pirenzepine - Unlicensed use in Clozapine related hypersalivation (approved 2009).pdf [pdf] 32KB
• Reboxetine Drug position statement (approved 2011).pdf [pdf] 36KB
• Risperdal Consta - Unlicensed use above the licensed dose (approved 2009).pdf [pdf] 38KB
• Risperidone Consta - High dose Guidance (approved 2010).pdf [pdf] 37KB
• Substance Misuse Guidance (Enc 3B).pdf [pdf] 1MB
• Terazosin - Use in Hypersalivation (approved 2017).pdf [pdf] 121KB
• Topiramate - Unlicensed use as a mood stabiliser (approved 2012).pdf [pdf] 66KB
• Topiramate - Unlicensed use in post traumatic stress disorder Bulimia Nervosa (approved 2009).pdf [pdf] 32KB
• Trazodone - Unlicensed use in the treatment of the behavioural and psychological symptoms of dementia (approved 2011).pdf [pdf] 40KB
  • Tryptophan – Shared Care Agreement SCA049 (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Valproate - Continuing prescribing in CWPT for females up to 55 years [pdf] 98KB
• Valproate - Initiating prescribing in CWPT for females up to 55 years [pdf] 97KB
• Valproate - Initiating prescribing in CWPT for males up to 55 years old [pdf] 92KB
• Valproate MHRA Guidance approved May 2024 D&T[pdf] 501KB
  
  • Valproate & Valproic Acid – Shared Care Agreement (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
  • Vortioxetine – Drug Position Statement (This link will re-direct you to the Area Prescribing Committee website. Type in the name of the drug required in the netFormulary search box)
• Valproic acid formulation comparison